SENSEX NIFTY

Pharma

Nov 24, 2014 at 15:24 | Source: Moneycontrol.com
AstraZeneca Pharma India Ltd has informed BSE that Mr. Robert Haxton has resigned as the Wholetime Director of the Company. The Board has accepted the resignation of Mr. Haxton and that he would be relieved from the said position, effective December 14, 2014.
Nov 21, 2014 at 18:02 | Source: CNBC-TV18
Anand Tandon says, one should look at stocks where there is still value. "If one looks at market as a whole there are still sectors available that are reasonably cheap like IT which has been ignored because growth rate is presumed to be slower than other cyclicals," he adds.
Nov 21, 2014 at 17:14 | Source: Moneycontrol.com
Aurobindo Pharma has informed that a meeting of the Board of Directors of the Company will be held on November 25, 2014, to consider raising of funds through issue of securities.
Nov 21, 2014 at 15:27 | Source: CNBC-TV18
Krish Subramanyam of Asit C Mehta Investment recommends buying KPIT Technologies and Marksans Pharma.
Nov 21, 2014 at 13:47 | Source: Moneycontrol.com
The multinational pharmaceutical company with current market capitalisation of nearly Rs 51,000 crore has a portfolio that includes 2000 products in 65 therapeutic categories with one quality standard globally.
Nov 21, 2014 at 12:46 | Source: Moneycontrol.com
Brokerage house Firstcall Research is bullish on Natco Pharma and has recommended buy rating on the stock with a target price of Rs 1550 in its research report dated November 18, 2014.
Nov 21, 2014 at 12:19 | Source: CNBC-TV18
Paras Bothra of Ashika Stock Broking is of the view that one can buy Marksans Pharma and Thomas Cook.
Nov 21, 2014 at 10:00 | Source: CNBC-TV18
Ajay Srivastava is bullish on cement, tyre, IT and pharma space. Among stocks, Srivastava likes JK Lakshmi, Shree cement, Sun Pharma, Lupin, Tech Mahindra, Infosys and Oracle.
Nov 21, 2014 at 08:51 | Source: CNBC-TV18
Vishal Kshatriya of Edelweiss recommends buying Hexaware Technologies for a target price of Rs 235-240 and Cipla with a target of Rs 640.
Nov 21, 2014 at 08:50 | Source: CNBC-TV18
Paras Bothra of Ashika Stock Broking recommends buying Arvind for a target price of Rs 320 and Hexaware Technologies for a target price of Rs 250.
Messages on Pharma »

subs74

Silver Member

3 Followers

Biocon  

Namo baba, at the end of the day its about fundamentals as also whether stock is in strong hands. pls look at other midcap pharma stocks like cadila, zydus,ipca. They have all gone up even on such a day despite having run up already which means they are in strong hands who dont allow the stocks

4.54 PM Jul 8th

abhishek_co
ssipore

New Member

1 Followers

Dishman Pharma  

Hold Dishman Pharma Targe Price 205

4.48 PM Jul 8th

subs74

Silver Member

3 Followers

Biocon  

I can understand a minor correction due to market sentiment but a 7% fall in a pharma stock like Biocon on the day of railway budget with which it has no correlation is strange. Either the correction is silly or the upmove itself in Biocon was not based on any fundamentals.

4.33 PM Jul 8th

Ajanta Pharma  

After AGM the share price will shoot up towards benefits to all investers - My target for Ajanta Pharma is Rs 2500 for the long term with a stoploss of Rs 1499

4.30 PM Jul 8th

Ravi_jangra

New Member

0 Follower

Alembic Pharma  

Salute to alembic pharma....All stocks down but alembic not....Guys today see alembic strong unbreakable resistance on 300/-.This is righttime to entre now or never...Save me today from huge lose

4.19 PM Jul 8th

jagoinvesto
r

Platinum Member

113 Followers

Morepen Lab  

morepen to buy sun pharma

4.15 PM Jul 8th

JPInvestor

New Member

0 Follower

SMS Pharma  

my view is that the equity base of SMS Pharma is very small and already having good profit. hence it can easily cross the above figures.

3.55 PM Jul 8th

subs74

Silver Member

3 Followers

Biocon  

How does budget affect pharma stocks like biocon?

3.47 PM Jul 8th

shmarketgen
ius

Platinum Member

587 Followers

Tech Mahindra  

suggest,that you try & find a small/mid- cap Pharma/IT/Auto Ancillary company or a consumer play.These stories are huuuge in size & will pay rich dividends.

3.47 PM Jul 8th

countryman

Platinum Member

625 Followers

Granules India  

For solving the problem of CAD, Re cannot go down so much to probably 53 levels which will hurt the exporters. I understand that RBI will control Re between 58 to 61 level so that exporters will get benefitted. Company has expanded their facilities, bought Auctus Pharma and this year Auctus

3.36 PM Jul 8th

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.